News Quantified

AVBP – arrivent biopharma, inc. (US:NASDAQ)

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

12/11

06:28 am

avbp

Low

ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.

ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.

ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.

ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}